ABSTRACT
In order to understand the clinical research progress of epidermal growth factor receptor inhibitors,the author reviewed the related research and literature report.It considers that cetuximab is mainly used for colorectal cancer without KRAS gene mutations,and trastuzumab is mainly used for breast cancer and gastric cancer with over expression of HER-2,and gefitinib and icotinib is mainly used for non-small cell lung adenocarcinoma with EGFR gene mutations.The above points of view can provide reference for the clinical application of these drugs.
ABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Subject(s)
Humans , Acneiform Eruptions , Carcinoma, Non-Small-Cell Lung , Clindamycin , Dermatology , Drug Therapy , Epidermal Growth Factor , Minocycline , SkinABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Subject(s)
Humans , Acneiform Eruptions , Carcinoma, Non-Small-Cell Lung , Clindamycin , Dermatology , Drug Therapy , Epidermal Growth Factor , Minocycline , SkinABSTRACT
PURPOSE: To introduce 2 cases of trichomegaly associated with the use of systemic epidermal growth factor receptor (EGFR) inhibitors for the treatment of lung cancer. CASE SUMMARY: An 82-year-old female visited our clinic for ocular pain in both eyes. She was suffering from metastatic lung cancer and was under daily treatment with gefitinib (Iressa(R), AstraZeneca, London, UK) for 6 months. On ophthalmologic examination, she presented with abnormally elongated eyelashes, hyperemic conjunctiva and dense corneal erosion. A 52-year-old male who was diagnosed with non-small cell lung cancer 7 months before and treated with erlotinib (Tarceva(R) OSI Pharmaceuticals, Inc., Melville, NY, USA) was referred to our clinic for injection and foreign body sensation in both eyes. Although there were no remarkable changes in eyelashes at the initial visit, long, curly, uneven eyelashes were observed after 3 months. CONCLUSIONS: Due to the increased use of EGFR inhibitors in anti-cancer treatment, ophthalmologists should be aware of these chemotherapeutics' adverse effects.
Subject(s)
Aged, 80 and over , Female , Humans , Male , Middle Aged , Carcinoma, Non-Small-Cell Lung , Conjunctiva , Eyelashes , Foreign Bodies , Lung Neoplasms , ErbB Receptors , Sensation , Erlotinib HydrochlorideABSTRACT
Objective: Using homogeneous time-resolved fluorescence (HTRF) technology to screen the Calla Chinensis extracts with anti-epidermal growth factor receptor activity and to analyze the active ingredients in Calla Chinensis by ultra-performance liquid chromatography/quadrupole-time of flight mass-spectrometry (UPLC/Q-TOF-MS). Methods: After percolation with petroleum ether, ethanol extract, ethyl acetate extraction, and boiling with water, four fractions were obtained. HTRF method was applied to detecting the inhibition of ethyl acetate fraction on EGFR, and the inhibitory rate was calculated. The chromatographic separation was performed on Acquity UPLC BEH C18 column with a gradient elufion of 0.1% formic acid water-acetonitrile. The mass spectrometer equipped with electrospay ionization source was used as defector, data were collected under the positive ion modes, and screened at 200-400 nm. Results: The ethyl acetate fraction of Calla Chinensis showed the strong inhibitory activity on EGFR. Fourteen compounds were analyzed and identified, among which tannins were the main active components, the 11 tannin compounds were punicalin, vanillin, di-HHDP-glucose, ellagitannin, myricetin 3-O-rhamnoside, protocatechuic acid, gallotannin-glucose, ellagic acid-hexose, 3, 5-dicaffeoylquinic acid, monogalloyl-glucose, and gallotannin, and the three others were unknown. Conclusion: The ethyl acetate fraction of Calla Chinensis has the significant EGFR inhibitory activity, and the IC50 value is 5.528 μg/mL. Tannins, including Chinese tannin, gallogen, and ellagitannin as main constituents, are identified through the information of positive ion and relative molecular mass determined by Q-TOF-MS. The results indicate that Calla Chinensis contains tannin ingredients to inhibit EGFR, in the hope to provide a theoretical basis of the application in anticancer and to lay the foundation for the further tracking separation of the active ingredients.
ABSTRACT
Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.
Subject(s)
Humans , Middle Aged , Butylated Hydroxytoluene , Lung , Lung Neoplasms , Protein-Tyrosine Kinases , Quinazolines , ErbB Receptors , Tongue, Hairy , Erlotinib HydrochlorideABSTRACT
Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor. Patients undergoing anti-EGFR therapy frequently present with cutaneous reactions like a sterile follicular and pustular rash, xerosis, pruritus, paronychia, hair abnormalities and mucositis, which can cause serious discomfort and negatively affect the compliance with anti-EGFR therapy. We report here on an interesting case of hair abnormalities induced by erlotinib (Tarceva(R)) and this presented as eyelash lengthening and hair curling in a 62-year-old woman.
Subject(s)
Female , Humans , Middle Aged , Adenosine Triphosphate , Binding, Competitive , Compliance , Exanthema , Hair , Mucositis , Paronychia , Polyphosphates , Protein-Tyrosine Kinases , Pruritus , Quinazolines , ErbB Receptors , Erlotinib HydrochlorideABSTRACT
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile follicular and pustular rash that may be treated empirically and usually does not require treatment modification. Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis. According to the Korean literature, there are no reports of acneiform eruption induced by erlotinib (Tarceva(R)). We report a case of acneiform eruption induced by cetuximab (Erbitux(R)) and a case of acneiform eruption induced by erlotinib (Tarceva(R)).